Boston University Medical School and LUV Systems Execute Low-UVC COVID-19 Research Agreement

BOSTON, MA (August 18, 2020) - Boston University School of Medicine and LUV Systems, Inc. today announced the execution of a research agreement under which Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) will conduct controlled studies on the inactivation of SARS-CoV-2 (COVID-19) using low-wavelength ultraviolet (UVC) light.

The research will evaluate the effectiveness of UVC across a range of wavelengths and real-world surface materials, including upholstery, stainless steel, and granite. The program is designed to generate critical validation data on both surface and airborne viral inactivation, with an emphasis on applications in occupied public environments.

This collaboration represents an important step in advancing LUV Systems’ technology platform by establishing third-party validation from a leading biosafety laboratory. The findings are expected to further inform product design, dosing methodologies, and commercial deployment strategies.

UV disinfection has been used for more than a century across healthcare, laboratory, and water treatment applications, underscoring its proven efficacy and broad market acceptance. While prior research has demonstrated UVC inactivation of COVID-19 at wavelengths such as 254 nm and 222 nm in controlled laboratory settings, limited data exists on real-world materials or across a broader spectrum of UVC wavelengths.

Emerging evidence indicates that certain lower UVC wavelengths, particularly near or below 222 nanometers, may enable effective pathogen inactivation while minimizing impact on mammalian tissues under controlled exposure conditions. The NEIDL study aims to expand the scientific understanding of these effects in practical use cases.

The research supports LUV Systems’ broader intellectual property strategy, following its previously announced patent filings covering multiple inventions designed to enable continuous disinfection of air and surfaces in occupied environments without direct human exposure. These applications span a wide range of use cases, including healthcare, transportation, commercial environments, and personal devices.

Neeraj Chaudhary, Business Analyst at LUV Systems, highlighted the commercial significance:  “This agreement with Boston University provides a critical validation pathway for our technology. The data generated will support the development of scalable, affordable disinfection solutions and accelerate our path to commercialization across multiple high-demand sectors.”

LUV Systems’ product development strategy is built around three core value drivers:

• Proven Effectiveness against a broad range of airborne pathogens and allergens
• Engineered Safety for use in occupied environments, including around people and pets; and
• Affordability to enable widespread adoption across consumer and commercial markets.

To further support performance and scalability, LUV Systems has developed a proprietary dosing algorithm that correlates surface viral inactivation data with effective indoor air disinfection rates, enabling predictable and measurable outcomes across diverse applications.

The NEIDL research program is expected to play a key role in advancing LUV Systems’ product roadmap and positioning the company for commercialization in global markets addressing indoor air quality and infection control.